PMID- 24815454
OWN - NLM
STAT- MEDLINE
DCOM- 20150110
LR  - 20220330
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 15
IP  - 7
DP  - 2014
TI  - TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer 
      patients from Eastern China.
PG  - 3099-103
AB  - TMPRSS2:ERG gene fusions in prostate cancer have a dominant prevalence of 
      approximately 50.0%, but infomration is limited on differences among ethnic and 
      geographical groups. Some studies focusing on Japanese and Korean patients 
      reported a lower incidence. Investigations concerning Chinese revealed 
      controversial results. We evaluated TMPRSS2:ERG, TMPRSS2:ETV1 and TMPRSS2:ETV4 
      fusions in more than 100 Eastern Chinese prostate cancer patients. Paraffin 
      blocks of needle biopsy and radical prostatectomy were collected from 91 and 18 
      patients respectively. All patients' clinicopathologic factors were gathered. 
      TMPRSS2:ERG, TMPRSS2:ETV1 and TMPRSS2:ETV4 fusions were tested by multi-probe 
      fluorescence in situ hybridization (FISH) assay. TMPRSS2:ERG fusions was present 
      in 14.3% biopsy specimens and 11.1% radical prostatectomy patients. Neither 
      TMPRSS2:ETV1 nor TMPRSS2:ETV4 fusion was found in any case. Altogether, 13 
      (86.7%) TMPRSS2:ERG fusion positive cases possessed deletion pattern and 7 
      (46.6%) and insertion pattern. Some 5 cases had both deletion and insertion 
      patterns. While 38.5% (5/13) patients with deletion pattern had distant 
      metastasis, except for one metastatic case harboring both deletion and insertion, 
      there were no patients with insertion pattern accompanied with metastasis. There 
      were no differences between fusion positive and negative cases in the 
      distribution of age, PSA, Gleason score and TNM stage. Eastern Chinese prostate 
      cancer patients have a significantly low incidence of TMPRSS2:ERG fusion. They 
      also lack TMPRSS2:ETV1 and TMPRSS2:ETV4 fusion. There are more deletion pattern 
      than insertion pattern in TMPRSS2:ERG positive cases. Fusion positive and 
      negative patients have no clinicopathologic factor differences.
FAU - Dong, Jun
AU  - Dong J
AD  - Department of Urology, Huadong Hospital, Fudan University, Shanghai, China E-mail 
      : drzhongquan@sina.com.
FAU - Xiao, Li
AU  - Xiao L
FAU - Sheng, Lu
AU  - Sheng L
FAU - Xu, Jun
AU  - Xu J
FAU - Sun, Zhong-Quan
AU  - Sun ZQ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Adenovirus E1A Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (ERG protein, human)
RN  - 0 (ETV1 protein, human)
RN  - 0 (ETV4 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Adenovirus E1A Proteins/*genetics
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Needle
MH  - China
MH  - DNA-Binding Proteins/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Paraffin Embedding
MH  - Prostate/pathology
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*genetics/pathology/surgery
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-ets
MH  - Recombinant Fusion Proteins/genetics
MH  - Serine Endopeptidases/*genetics
MH  - Tissue Preservation
MH  - Trans-Activators/*genetics
MH  - Transcription Factors/*genetics
MH  - Transcriptional Regulator ERG
EDAT- 2014/05/13 06:00
MHDA- 2015/01/13 06:00
CRDT- 2014/05/13 06:00
PHST- 2014/05/13 06:00 [entrez]
PHST- 2014/05/13 06:00 [pubmed]
PHST- 2015/01/13 06:00 [medline]
AID - 10.7314/apjcp.2014.15.7.3099 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014;15(7):3099-103. doi: 10.7314/apjcp.2014.15.7.3099.